201 related articles for article (PubMed ID: 12576431)
21. Tumor clearance of technetium 99m-sestamibi as a predictor of response to neoadjuvant chemotherapy for locally advanced breast cancer.
Ciarmiello A; Del Vecchio S; Silvestro P; Potena MI; Carriero MV; Thomas R; Botti G; D'Aiuto G; Salvatore M
J Clin Oncol; 1998 May; 16(5):1677-83. PubMed ID: 9586878
[TBL] [Abstract][Full Text] [Related]
22. Interrogation of multidrug resistance (MDR1) P-glycoprotein (ABCB1) expression in human pancreatic carcinoma cells: correlation of 99mTc-Sestamibi uptake with western blot analysis.
Harpstrite SE; Gu H; Natarajan R; Sharma V
Nucl Med Commun; 2014 Oct; 35(10):1067-70. PubMed ID: 25036383
[TBL] [Abstract][Full Text] [Related]
23. Non-small cell lung cancer functional imaging: increased hexakis-2-methoxy-isobutyl-isonitrile tumor clearance correlates with resistance to cytotoxic treatment.
Koukourakis MI; Koukouraki S; Giatromanolaki A; Skarlatos J; Georgoulias V; Karkavitsas N
Clin Cancer Res; 1997 May; 3(5):749-54. PubMed ID: 9815745
[TBL] [Abstract][Full Text] [Related]
24. A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer.
Kelly RJ; Draper D; Chen CC; Robey RW; Figg WD; Piekarz RL; Chen X; Gardner ER; Balis FM; Venkatesan AM; Steinberg SM; Fojo T; Bates SE
Clin Cancer Res; 2011 Feb; 17(3):569-80. PubMed ID: 21081657
[TBL] [Abstract][Full Text] [Related]
25. Fractional retention of technetium-99m-sestamibi as an index of P-glycoprotein expression in untreated breast cancer patients.
Del Vecchio S; Ciarmiello A; Pace L; Potena MI; Carriero MV; Mainolfi C; Thomas R; D'Aiuto G; Tsuruo T; Salvatore M
J Nucl Med; 1997 Sep; 38(9):1348-51. PubMed ID: 9293785
[TBL] [Abstract][Full Text] [Related]
26. Comparison of the accumulation and efflux kinetics of technetium-99m sestamibi and technetium-99m tetrofosmin in an MRP-expressing tumour cell line.
Utsunomiya K; Ballinger JR; Piquette-Miller M; Rauth AM; Tang W; Su ZF; Ichise M
Eur J Nucl Med; 2000 Dec; 27(12):1786-92. PubMed ID: 11189941
[TBL] [Abstract][Full Text] [Related]
27. Tc-99m MIBI liver imaging for hepatocellular carcinoma: correlation with P-glycoprotein-multidrug-resistance gene expression.
Chang CS; Yang SS; Yeh HZ; Kao CH; Chen GH
Hepatogastroenterology; 2004; 51(55):211-4. PubMed ID: 15011866
[TBL] [Abstract][Full Text] [Related]
28. In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576.
Mistry P; Stewart AJ; Dangerfield W; Okiji S; Liddle C; Bootle D; Plumb JA; Templeton D; Charlton P
Cancer Res; 2001 Jan; 61(2):749-58. PubMed ID: 11212278
[TBL] [Abstract][Full Text] [Related]
29. Technetium-99m sestamibi imaging in paediatric neuroblastoma and ganglioneuroma and its relation to P-glycoprotein.
De Moerloose B; Van de Wiele C; Dhooge C; Philippé J; Speleman F; Benoit Y; Laureys G; Dierckx RA
Eur J Nucl Med; 1999 Apr; 26(4):396-403. PubMed ID: 10199946
[TBL] [Abstract][Full Text] [Related]
30. Effect of P-glycoprotein and multidrug resistance associated protein gene expression on Tc-99m MIBI imaging in hepatocellular carcinoma.
Chang CS; Huang WT; Yang SS; Yeh HZ; Kao CH; Chen GH
Nucl Med Biol; 2003 Feb; 30(2):111-7. PubMed ID: 12623109
[TBL] [Abstract][Full Text] [Related]
31. Studies of the myocardial uptake and excretion mechanisms of a novel 99mTc heart perfusion agent.
Mendes F; Gano L; Fernandes C; Paulo A; Santos I
Nucl Med Biol; 2012 Feb; 39(2):207-13. PubMed ID: 22079035
[TBL] [Abstract][Full Text] [Related]
32. Technetium-99m-hexakis-2-methoxyisobutylisonitrile scintigraphy and multidrug resistance-related protein expression in human primary lung cancer.
Duan XY; Wang JS; Liu M; Guo YM
Ann Nucl Med; 2008 Jan; 22(1):49-55. PubMed ID: 18250987
[TBL] [Abstract][Full Text] [Related]
33. 99mTc-Sestamibi scanning with SDZ PSC 833 as a functional detection method for resistance modulation in patients with solid tumours.
Bakker M; van der Graaf WT; Piers DA; Franssen EJ; Groen HJ; Smit EF; Kool W; Hollema H; Müller EA; De Vries EG
Anticancer Res; 1999; 19(3B):2349-53. PubMed ID: 10472354
[TBL] [Abstract][Full Text] [Related]
34. Does the Clearance of Inhaled (99m)Tc-Sestamibi Correlate with Multidrug Resistance Protein 1 Expression in the Human Lung?
Mohan HK; Routledge T; Cane P; Livieratos L; Ballinger JR; Peters AM
Radiology; 2016 Sep; 280(3):924-30. PubMed ID: 26954010
[TBL] [Abstract][Full Text] [Related]
35. Technetium-99m-sestamibi uptake by human benign and malignant breast tumor cells: correlation with mdr gene expression.
Cordobes MD; Starzec A; Delmon-Moingeon L; Blanchot C; Kouyoumdjian JC; Prévost G; Caglar M; Moretti JL
J Nucl Med; 1996 Feb; 37(2):286-9. PubMed ID: 8667063
[TBL] [Abstract][Full Text] [Related]
36. Expression of recombinant human multidrug resistance P-glycoprotein in insect cells confers decreased accumulation of technetium-99m-sestamibi.
Rao VV; Chiu ML; Kronauge JF; Piwnica-Worms D
J Nucl Med; 1994 Mar; 35(3):510-5. PubMed ID: 7906729
[TBL] [Abstract][Full Text] [Related]
37. Myocardial technetium-99m-tetrofosmin and technetium-99m-sestamibi kinetics in normal subjects and patients with coronary artery disease.
Münch G; Neverve J; Matsunari I; Schröter G; Schwaiger M
J Nucl Med; 1997 Mar; 38(3):428-32. PubMed ID: 9074532
[TBL] [Abstract][Full Text] [Related]
38. Technetium-99m methoxyisobutylisonitrile imaging for parathyroid adenoma: relationship to P-glycoprotein or multidrug resistance-related protein expression.
Kao A; Shiau YC; Tsai SC; Wang JJ; Ho ST
Eur J Nucl Med Mol Imaging; 2002 Aug; 29(8):1012-5. PubMed ID: 12173014
[TBL] [Abstract][Full Text] [Related]
39. 99mTc-N-DBODC5, a new myocardial perfusion imaging agent with rapid liver clearance: comparison with 99mTc-sestamibi and 99mTc-tetrofosmin in rats.
Hatada K; Riou LM; Ruiz M; Yamamichi Y; Duatti A; Lima RL; Goode AR; Watson DD; Beller GA; Glover DK
J Nucl Med; 2004 Dec; 45(12):2095-101. PubMed ID: 15585487
[TBL] [Abstract][Full Text] [Related]
40. 99mTc-MIBI whole body scintigraphy and P-glycoprotein for the prediction of multiple drug resistance in multiple myeloma patients.
Fallahi B; Beiki D; Mousavi SA; Gholamrezanezhad A; Eftekhari M; Fard-Esfahani A; Alimoghaddam K; Mirpour S; Eskandarian A; Saghari M
Hell J Nucl Med; 2009; 12(3):255-9. PubMed ID: 19936339
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
